BIRB796, the Inhibitor of p38 Mitogen-Activated Protein Kinase, Enhances the Efficacy of Chemotherapeutic Agents in ABCB1 Overexpression Cells

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  He, Dan ^a   Zhao, Xiao qin ^b   Chen, Xing gui ^b   Fang, Yi ^b   Singh, Satyakam ^c   Talele, Tanaji T ^c   Qiu, Hui juan ^b   Liang, Yong ju ^b   Wang, Xiao kun ^b   Zhang, Guo qing ^a   Chen, Zhe sheng ^c   Fu, Li wu ^b  

^a XINJIANG MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c ST JOHN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C1; ADENOSINE TRIPHOSPHATASE; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; DORAMAPIMOD; DOXORUBICIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PLACEBO; RHODAMINE 123; SMALL INTERFERING RNA; SYNAPTOPHYSIN; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; CANCER INHIBITION; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; EXPERIMENTAL MOUSE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; NONHUMAN; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HL-60 CELLS; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NAPHTHALENES; NEOPLASMS; P-GLYCOPROTEIN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PACLITAXEL; PROTEIN KINASE INHIBITORS; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84872518517     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054181     Document Type: Article

References (47)

1. Dean M, Rzhetsky A, Allikmets R, (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11: 1156-1166.
2. Sarkadi B, Homolya L, Szakacs G, Varadi A, (2006) Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86: 1179-1236.
3. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, et al. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398.
4. Teodori E, Dei S, Martelli C, Scapecchi S, Gualtieri F, (2006) The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr Drug Targets 7: 893-909.
5. Germann UA, (1996) P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A: 927-944.
6. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, et al. (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 84: 265-269.
7. Leonard GD, Fojo T, Bates SE, (2003) The role of ABC transporters in clinical practice. Oncologist 8: 411-424.
8. Jamroziak K, Robak T, (2004) Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology 9: 91-105.
9. Lage H, (2006) MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr Drug Targets 7: 813-821.
10. Rees DC, Johnson E, Lewinson O, (2009) ABC transporters: the power to change. Nat Rev Mol Cell Biol 10: 218-227.
11. Doyle LA, Ross DD, (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340-7358.
12. Bakos E, Homolya L, (2007) Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch 453: 621-641.
13. Wilson KP, Fitzgibbon MJ, Caron PR, Griffith JP, Chen W, et al. (1996) Crystal structure of p38 mitogen-activated protein kinase. J Biol Chem 271: 27696-27700.
14. Ranganathan AC, Adam AP, Zhang L, Aguirre-Ghiso JA, (2006) Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells. Cancer Biol Ther 5: 729-735.
15. Cuenda A, Rousseau S, (2007) p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773: 1358-1375.
16. Regan J, Capolino A, Cirillo PF, Gilmore T, Graham AG, et al. (2003) Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]urea (BIRB 796). J Med Chem 46: 4676-4686.
17. Alsayed Y, Uddin S, Mahmud N, Lekmine F, Kalvakolanu DV, et al. (2001) Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem 276: 4012-4019.
18. Verma A, Mohindru M, Deb DK, Sassano A, Kambhampati S, et al. (2002) Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem 277: 44988-44995.
19. Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, et al. (2004) p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23: 8766-8776.
20. Barancik M, Bohacova V, Kvackajova J, Hudecova S, Krizanova O, et al. (2001) SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 14: 29-36.
21. Paillas S, Boissiere F, Bibeau F, Denouel A, Mollevi C, et al. (2011) Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. Cancer Res 71: 1041-1049.
22. Schreiber S, Feagan B, D'Haens G, Colombel JF, Geboes K, et al. (2006) Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4: 325-334.
23. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, et al. (2008) Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 68: 7905-7914.
24. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, et al. (2003) Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89: 1971-1978.
25. Wang F, Liang YJ, Wu XP, Su XD, Fu LW, (2012) ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties. Chin J Cancer 31: 150-158.
26. Ding PR, Tiwari AK, Ohnuma S, Lee JW, An X, et al. (2011) The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLOS ONE 6: e19329.
27. Tang R, Faussat AM, Majdak P, Perrot JY, Chaoui D, et al. (2004) Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 18: 1246-1251.
28. Zhao XQ, Xie JD, Chen XG, Sim HM, Zhang X, et al. (2012) Neratinib (HKI-272) Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance in Vitro, in Vivo and ex Vivo. Mol Pharmacol.
29. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, et al. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323: 1718-1722.
30. Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, et al. (2011) Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res 71: 3029-3041.
31. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, et al. (2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9: 268-272.
32. Chen LM, Liang YJ, Ruan JW, Ding Y, Wang XW, et al. (2004) Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. J Pharm Pharmacol 56: 1061-1066.
33. Regan J, Breitfelder S, Cirillo P, Gilmore T, Graham AG, et al. (2002) Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J Med Chem 45: 2994-3008.
34. Guo X, Ma N, Wang J, Song J, Bu X, et al. (2008) Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer 8: 375.
35. Wacher VJ, Wu CY, Benet LZ, (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13: 129-134.
36. Atadja P, Watanabe T, Xu H, Cohen D, (1998) PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance. Cancer Metastasis Rev 17: 163-168.
37. Krishna R, Mayer LD, (2001) Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators. Curr Med Chem Anticancer Agents 1: 163-174.
38. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, et al. (2007) Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67: 11012-11020.
39. Tao LY, Liang YJ, Wang F, Chen LM, Yan YY, et al. (2009) Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol 64: 961-969.
40. Zheng LS, Wang F, Li YH, Zhang X, Chen LM, et al. (2009) Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLOS ONE 4: e5172.
41. Wang F, Mi YJ, Chen XG, Wu XP, Liu Z, et al. (2012) Axitinib targeted cancer stem-like cells to enhance efficacy of chemotherapeutic drug via inhibiting the drug transport function of ABCG2.LID- 10.2119/molmed.2011.00444 [doi]. Mol Med.
42. Klepsch F, Jabeen I, Chiba P, Ecker GF, (2010) Pharmacoinformatic approaches to design natural product type ligands of ABC-transporters. Curr Pharm Des 16: 1742-1752.
43. Klopman G, Shi LM, Ramu A, (1997) Quantitative structure-activity relationship of multidrug resistance reversal agents. Mol Pharmacol 52: 323-334.
44. Crivori P, Reinach B, Pezzetta D, Poggesi I, (2006) Computational models for identifying potential P-glycoprotein substrates and inhibitors. Mol Pharm 3: 33-44.
45. Pajeva IK, Globisch C, Wiese M, (2009) Combined pharmacophore modeling, docking, and 3D QSAR studies of ABCB1 and ABCC1 transporter inhibitors. ChemMedChem 4: 1883-1896.
46. Osborn MT, Berry A, Ruberu MS, Ning B, Bell LM, et al. (1999) Phorbol ester induced MDR1 expression in K562 cells occurs independently of mitogen-activated protein kinase signaling pathways. Oncogene 18: 5756-5764.
47. Branger J, den Blink B v, Weijer S, Madwed J, Bos CL, et al. (2002) Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 168: 4070-4077.